Changes in neuropsychological functioning following treatment with risperidone, olanzapine, and conventional antipsychotic medications

Human Psychopharmacology

Volumn 23, Issue 7, 2008, Pages 595-604

  Jerrell, Jeanette M ^a   Ramirez, Paul Michael ^b  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b LONG ISLAND UNIVERSITY   (United States)

Author keywords

Functioning outcomes; Neuropsychological changes; Olanzapine; Risperidone; Schizophrenia; Symptomatology outcomes

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; ATTENTION; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHOLOGICAL TEST; NEUROPSYCHOLOGY; OPEN STUDY; PATIENT MONITORING; PRIORITY JOURNAL; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYMPTOMATOLOGY; VERBAL MEMORY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL PROCESSES; NEUROPSYCHOLOGICAL TESTS; PROSPECTIVE STUDIES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR PERFORMANCE; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 57149125052     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.967     Document Type: Article

References (47)

1. Andersson C, Chakos M, Mailman R, Lieberman J. 1998. Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. Psychiatr Clin N Am 21: 151-179.
2. Benton AL, Hamsher K, Sivan AB. 1994. Multilingual Aphasia Examination, (3rd edn). AJA Associates: Iowa City, IA.
3. Bilder RM, Goldman RS, Volavka J, et al. 2002. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol inpatients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018-1028.
4. Blyler CR, Gold JM. 2001. Cognitive effects of typical antipsychotic treatment: another look. In Cognition in Schizophrenia: Impairments, Importance, and Treatment Strategies, Sharma T, Harvey PD (eds). Oxford University Press: New York; 241-265.
5. Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. 1990. Neuroleptics on neuropsychological function in chronic schizophrenic patients. Schizophr Bull 16: 477-499.
6. Classen W, Laux G. 1988. Sensorimotor and cognitive performance of schizophrenic inpatients treated with haloperidol, flupenthixol, or clozapine. Pharmacopsychiatric 21: 295-297.
7. Crismon ML, Dorson PG. 1997. Schizophrenia. In Pharmacotherapy: A Pathophysiologic Approach, 3rd edn, Dipiro JT, Bosso JA, Carson DS, Chessman KH, Nappi JM (eds). Appelton and Lange: Stamford, CT; 1375.
8. Drachman DA. 1977. Memory and cognitive function in man: does the cholinergic system have a specific role? Neurology 27: 783-7790.
9. Earle-Boyer EA, Serper MR, Davidson M, Harvey PD. 1991. Continuous performance tests in schizophrenia patients: stimulus and medication effects on performance. Psychiatr Res 37: 37-46.
10. Golden CJ. 1978. The Stroop Color and Word Test. Stolting Co: Chicago, IL.
11. Goodglass H, Kaplan E. 1987. The Assessment of Aphasia and Related Disorders, (2nd edn). Lea and Febiger: Philadelphia, PA.
12. Green MF, Kern RS, Braff DL, Mintz J. 2000. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring "the right stuff?". Schizophr Bull 26: 119-136.
13. Green MF, Marshall BD Jr, Wirshing WC, et al. 1997. Does risperidone improve verbal working memory in schizophrenia? Am J Psychiatry 154: 799-804.
14. Harvey PD. 2003. Ziprasidone and cognition: the evolving story. J Clin Psychiatry 64(suppl 19): 33-39.
15. Harvey PD, Green MF, McGurk SR, Meltzer HY. 2003. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology 169: 404-411.
16. Harvey PD, Keefe RS. 2001. Studies of cognitive change inpatients with schizophrenia following novel antipsychotic treatment. Am J Psychiatry 158: 176-184.
17. Heaton RK, Crowley TJ. 1981. Effect of psychiatric disorders and their somatic treatments on neuropsychological test results. In Handbook of Clinical Neuropsychology, Filskov S, Boll TJ (eds). John Wiley & Sons: New York; 481-525.
18. Heinrichs RW. 2007. Cognitive improvement in response to antipsychotic drugs. Arch Gen Psychiatry 64: 631-632.
19. Jerrell JM. 2002. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull 28: 589-605.
20. Kay SG, Fiszbein A, Opler LA. 1987. The positive and negative syndrome scale for schizophrenia. Schizophr Bull 13: 261-276.
21. Keefe RSE, Bilder RM, Davis SM, et al. 2007. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64: 633-647.
22. Keefe RSE, Seidman LJ, Christensen BK, et al. 2004. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, doubleblind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 161: 985-995.
23. Kenny JT, Meltzer HY. 1991. Attention and higher cortical functions in schizophrenia. Neuropsychiatry Clin Neurosci 3: 269-275.
24. Kern RS, Green MF, Marshall BD Jr, et al. 1998. Risperidone vs. haldoperidol on reaction time, manual dexterity, and motor learning in treatment-resistant schizophrenia patients. Biol Psychiatry 44: 726-732.
25. King DJ. 1990. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry 157: 799-811.
26. Landro NI. 1994. Memory function in schizophrenia. Acta Psychiatrica Scandinavia 90: 87S-94S.
27. Ljubin T, Milas DZ, Mimica N, Folnegovic-Smalc V, Makaric G. 2000. A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients. Hum Psychopharmacol 15: 513-519.
28. McGurk SR, Green MF, Wirshing WC, et al. 1997. The effects of risperidone vs. haldoperidol on cognitive functioning in treatment-resistant schizophrenia: the trail making test. CNS Spectr 2: 60-64.
29. Medalia A, Gold J, Merriam A. 1988. The effects of neuroleptics on neuropsychological test results in schizophrenia. Arch Clin Neuropsychol 3: 249-271.
30. MeltzerHY, McGurk SR. 1999. Effects of atypical antipsychotics on cognition. Schizophr Bull 25: 233-255.
31. Overall JE, Gorham DR. 1962. The Brief Psychiatric Rating Scale. Psychol Rep 10: 799-812.
32. Purdon SE, Jones BDW, Stip E, et al. 2000. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57: 249-258.
33. Purdon SE, Labelle A, Boulay L. 2001. Neuropsychological change in schizophrenia after 6 weeks of clozapine. Schizophr Res 48: 57-67.
34. Reidel M, Spellman I, Strassnig M, et al. 2007. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms. Eur Arch Psychiatry Clin Neurosci 257: 360-370.
35. Reitan RM, Wolfson D. 1985. The Halstead-Reitan Neuropsychological Test Battery. Neuropsychology Press: Tucson, AZ.
36. Rossi A, Mancini F, Stratta P, et al. 1997. Risperidone, negative symptoms, and cognitive deficit in schizophrenia: an open study. Acta Psychiatrica Scandinavica 95: 40-43.
37. Spohn HE, Strauss ME. 1989. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnorm Psychol 98: 367-380.
38. Spreen O, Benton A. 1977. Neurosensory Center Comprehensive Examination for Aphasia (NCCEA). University of Victoria Neuropsychological Laboratory: Victoria, Canada.
39. Stip F. 1996.Memory impairment in schizophrenia: perspectives from psychopathology and pharmacotherapy. Canadian J Psychiatry - Revue Canadienne de Psychiatrie 41 (8 suppl 2): S27-S34.
40. Stip F, Lussier I. 1996. The heterogeneity of memory dysfunction in schizophrenia. Canadian J Psychiatry - Revue Canadienne de Psychiatrie 41 (9 suppl 1): S14-S20.
41. Strauss ME. 1993. Relations of symptoms to cognitive deficits in schizophrenia. Schizophr Bull 19(2): 215-231.
42. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL. 2000. Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nervous Mental Disord 188: 518-524.
43. Wechsler D. 1981. Wechsler Memory Scale - Revised. Psychological Corporation: San Antonio, TX.
44. Wechsler D. 1991. WAIS-III Manual. Psychological Corporation: New York.
45. Wei LJ, Lachin JM. 1988. Properties of the urn randomization method in clinical trials. Controll Clin Trials 9: 345-364.
46. Woodward ND, Purdon SE, Meltzer HY, Zald DH. 2005. A metaanalysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8: 457-472.
47. Woodward ND, Purdon SE, Meltzer HY, Zald DH. 2007. A metaanalysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res 89: 211-224.